Navigation Links
Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Date:11/1/2007

SAN DIEGO, Nov. 1 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced completion of the company's Phase 1 clinical trial of AM103, Amira's internally discovered oral drug candidate for the treatment of inflammatory diseases linked to the leukotriene pathway. Amira also announced the start of a Phase 1 trial for AM803, a second oral drug candidate that targets the same inflammatory response.

AM103 and AM803 are novel inhibitors of 5-lipoxygenase-activiting protein (FLAP) that have demonstrated potential to treat asthma and cardiovascular disease (CVD) by preventing the synthesis of leukotrienes (LT), which trigger inflammation. The recently completed AM103 trial was designed to assess the safety and tolerability of an escalating single dose of the compound and escalating multiple doses in healthy volunteers who received AM103 or placebo for up to 11 days. The trial also assessed the pharmacodynamic properties of AM103, specifically its ability to inhibit LT production.

Results from the Phase 1 trial show that AM103 is safe and well-tolerated at doses up to 1,000 mg per day with no evidence of significant side effects. The systemic exposure of AM103 increased linearly from 50 mg to 1,000 mg.

Pharmacodynamic data demonstrated a robust and statistically significant reduction of LTB4 and LTE4 in a dose-dependent manner. "The results from this trial meet and even exceed our expectations for safety, and provide pharmacodynamic evidence consistent with this mechanism of action," said Peppi Prasit, Amira's chief scientific officer. "The half-life of up to 10 hours also gives us the opportunity to evaluate once-daily dosing in a Phase 2 trial, which we expect to start in 2008."

"Based on this very favorable profile, the excellent tolerability and the high levels of exposure obtained with oral dosing in Phase 1 studies, we are moving forward to conduct a Phase 2 study with AM103 in asthmatic patients," said Bob Baltera, Amira's chief executive
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Octo Consulting Group (Octo), an award-winning ... to the federal marketplace, has named Gaurav “GP” Pal ... this newly created role, Pal will be responsible for ... computing, big data, and digital services. , “We’re excited ... we continue to bring clients new and innovative solutions ...
(Date:5/26/2015)... May 26, 2015 Relias Learning ... for the health and human services market, announces expansion ... demand. After strong attendance and participation in 2014, they ... give their annual user conference an exciting new facelift. ... to come together and discuss best practices, share their ...
(Date:5/26/2015)... Pasadena, CA (PRWEB) May 26, 2015 ... is now offering complimentary dental cleanings with cosmetic treatments. ... , Cosmetic Dentistry , “We are committed ... giving you cutting-edge technology, outstanding customer service and a ... not only to change your smiles but to change ...
(Date:5/26/2015)... National Prevention Week , National Prevention Week ... supported by the Substance Abuse and Mental Health Services ... and action about, substance abuse as well as mental ... encouraged to join in promoting prevention strategies, in educating ... in building community partnerships. , The Voice of One, ...
(Date:5/26/2015)... York, NY (PRWEB) May 26, 2015 Award-winning ... for a good cause. "The photography show will connect viewers ... in their lives.” For the last five years, Raul has ... to convey the notion that we are not bounded by ... a language spoken in Raul’s native country, Bolivia. The photo ...
Breaking Medicine News(10 mins):Health News:Octo Consulting Group (Octo) Appoints Gaurav “GP” Pal as Vice President of Technology Strategy and Cloud Solutions 2Health News:Relias Learning Expands User Groups and Industry Influence 2Health News:Relias Learning Expands User Groups and Industry Influence 3Health News:Pasadena Porcelain Veneers Expert, Marine Martirosyan DDS, is Now Offering Complimentary Dental Cleaning with Cosmetic Treatments 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3Health News:A Photographer & Two Educational Organiazations Join to Make a Difference in Our Youth 2
... Time" a Valuable Present: Peake, WASHINGTON, Dec. 21 ... volunteers who remember our nation,s,veterans, especially those hospitalized in ... "Some of our patients will be unable to ... B. Peake, Secretary of Veterans Affairs. "The,good cheer and ...
... research suggests , FRIDAY, Dec. 21 (HealthDay News) -- Treating ... concludes a University of Pennsylvania School of Medicine study in ... , It found that providing depression care management to older ... over five years by about 50 percent. , "Depression is ...
... for ambulatory care ... ... Cardiac Science,Corporation, (Nasdaq: CSCX ), a leading provider of ... of its HeartCentrix(R) ECG informatics software with Greenway,Medical Technology,s PrimeSuite(R) ...
... Milk Processors and, Bally Total Fitness to Shape Up ... ... SILVER SPRING, Md., Dec. 21 Discovery Health,s fifth,annual NATIONAL ... biggest and best year yet, with online registration beginning on,December ...
... costs of providing comprehensive screening and diagnostic services to ... or cervical cancer for treatment. Dr. Donatus U. Ekwueme ... Health Promotion at the Centers for Disease Control and ... cost of screening a woman for breast cancer was ...
... 20 ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), ... Drug,Application (NDA) to the U.S. Food and Drug ... seeking approval for Xibrom QD,as a treatment for ... (bromfenac ophthalmic solution), Xibrom is a topical ...
Cached Medicine News:Health News:VA Salutes Volunteers' Spreading Holiday Cheer 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 3Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 4Health News:Discovery Health's Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle 2Health News:Discovery Health's Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle 3Health News:Study determines costs of breast and cervical cancer detection among low-income women 2Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2
(Date:5/26/2015)... -- Haemonetics Corporation (NYSE: HAE ) announced today that ... present at The East Coast IDEAS Investor Conference in ... , 2015 at 2:30pm Eastern time.  ... webcast at: http://www.wsw.com/webcast/threepa16/hae About ... global healthcare company dedicated to providing innovative blood management ...
(Date:5/26/2015)... -- Depomed, Inc. (NASDAQ: DEPO ) today announced that ... The 2015 Jefferies Healthcare Conference in New ... for 3:00 pm EDT (12:00 noon PDT) Tuesday, June 2, ... Conference in New York City.  The presentation at the JMP ... Wednesday, June 24, 2015. Both presentations will be ...
(Date:5/26/2015)... , England and PITTSBURGH , May ... a leading global pharmaceutical company, today announced that Mylan ... the Bernstein Strategic Decisions Conference, Friday, May 29, 2015 ... can access a live webcast of the presentation via ... http://mylan.com/investors . An archived version will also be available ...
Breaking Medicine Technology:Depomed To Present At Healthcare Conferences In June 2
... 2007 - Cytogen,Corporation (NASDAQ: CYTO) today announced ... at upcoming major medical meetings. The,data will ... QUADRAMET(R),(samarium Sm-153 lexidronam injection) in combination settings ... from prostate,cancer and multiple myeloma, as well ...
... of,In-Segment Late Loss, Non-Inferiority in Major Secondary Endpoint,of Target ... in the SPIRIT III U.S. Trial -, ABBOTT PARK, ... Abbott's SPIRIT III U.S. pivotal clinical,trial at the of ... following key results: , , -- ...
Cached Medicine Technology:New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 2New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 3New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 4New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 5Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 2Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 3Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 4Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 5
... Ergonomic Design for Unparalleled Comfort Pick one ... the balance. Notice the trigger and ejector positionsright ... because our pipettors are ergonomically designed to help ... of pipetting. Productivity In The Palm Of ...
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... Pick one of our pipettors up and ... and ejector positionsright where they should beeven if ... designed to help avoid repetitive stress injuries caused ... The Palm Of Your Hand Start dispensing ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... tip ejection with long, lever tip ejector ... , Accepts universal tips or for greater ...
Medicine Products: